OBJECTIVES: Compare economic, public health, and humanistic impact of  2 dose quadrivalent (HPV 6/11/16/18) vaccination for 9-11 year old females and males with  female only bivalent (HPV 16/18) vaccination  in Mexico. METHODS: A previously developed transmission dynamic mathematical model was adapted to evaluate impact of routine vaccination of 9-11 year old females and males in Mexico. The model compared 70% female and 50% male baseline coverage for two doses of quadrivalent vaccine versus 70% female bivalent vaccine coverage. Mexico specific data was used from literature where available; model default values were used otherwise. Input data included demographic, behavioral, epidemiological and screening parameters, and direct treatment costs of HPV-related morbidities from a public health perspective. RESULTS: Over a 100-year period, compared to bivalent female vaccination, female and male quadrivalent vaccination reduced incidence of male anal and penile cancer by 8.3% and 14.6% respectively and avoided 7.8% and 13.9% deaths in males from anal and penile cancers respectively. Female and male quadrivalent vaccination reduced HPV 6/11-related disease incidence of genital warts in females (84.5%) and males (84.1%), and CIN1 (83.5%). This would translate into a reduction of HPV 6/11-related disease cost of 61.7%, 60.9%, and 58% for genital warts among females and males, and HPV 6/11 related CIN1, respectively.  Over a 100 year period, the total HPV 6/11/16/18-related disease costs avoided would be over $2.12 billion Mexican Pesos. The incremental cumulative QALYs gained per 100,000 by HPV 6/11/16/18-related disease over 100 years would be 66.67 when compared with HPV16/18 vaccination. CONCLUSIONS: In Mexico, a quadrivalent HPV 6/11/16/18 routine vaccination program for 9-11 year old females and males has incremental economic, public health, and humanistic impact compared to a female only bivalent HPV 16/18 vaccination program and will further decrease the burden of HPV-related disease by preventing genital warts, anal and penile cancer.